Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9263091 | 0.85 | MEN1 (0.53) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL18759595 | 0.78 | MAPT (0.32) | CYP3A4MAPT | |
| SCHEMBL9390107 | 0.77 | MAPT (0.38) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL11295182 | 0.76 | MAPT (0.32) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL9256118 | 0.76 | ALDH1A1 (0.41) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL23787682 | 0.76 | TSHR (0.35) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10861366 | 0.76 | TSHR (0.40) | MEN1CYP3A4ALOX15KMT2AMAPT | |
| SCHEMBL614491 | 0.76 | TDP1 (0.35) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL21625685 | 0.74 | TSHR (0.41) | — | |
| SCHEMBL1472536 | 0.74 | MEN1 (0.46) | MEN1CYP3A4ALOX15KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682746-B1 | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | PHENOMENOME DISCOVERIES INC (CA) | 2017-05-24 | — | — | EP | disclosed |
| US-20160377623-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |